HIGHLAND-EUROPE
7.12.2020 13:33:03 CET | Business Wire | Press release
Highland Europe has strengthened its industry-renowned team with the promotion of Jean Tardy-Joubert, Gajan Rajanathan and Ronan Shally to Partner. Tardy-Joubert and Rajanathan joined Highland in 2017/18 from Qatalyst, the San Francisco-based boutique investment bank serving the global tech sector, while Shally has been with the firm since 2014 and is Highland’s Chief Financial Officer. By promoting Gajan, Jean and Ronan, Highland Europe is better positioned than ever to help the founders it backs to achieve their ambitions. Highland Europe is differentiated by a high-touch, collaborative approach to helping companies scale globally.
Highland Europe also announces today that it closed its fourth fund, raising €700M to double-down on its strategy of backing the continent’s most outstanding founder-led teams in software and internet businesses.
Building on a track record of investing in consumer tech brands and software companies such as AMCS, Brandwatch, ContentSquare, Featurespace, GetYourGuide, Huel, Jellysmack, MatchesFashion, Nexthink, PhotoBox, WeTransfer, Zwift and Wolt, the new fund takes Highland Europe’s assets under management to €1.8bn.
Over the past 12 months, the firm has backed seven exceptional founding teams investing nearly €200M in Alkemics, Cobalt, DominoDatalab, Farewill, Meditopia, Modulr and Supermetrics as well as the existing portfolio. Highland Europe’s portfolio companies attracted exceptional external investment appetite with €730M follow-on investment in the last 12 months, some of which fueled seven M&A transactions completed by portfolio companies. Last but not least, the team helped two founder-led teams (Spot and Smartly.io) navigate strategic and private equity interest, resulting in substantial liquidity events.
Just as mission-critical tech and innovation have been instrumental in enabling businesses and individuals to continue functioning during the pandemic, technology looks set to play a key role in an eventual economic recovery. Reflecting this, Highland saw significant commitment from investors, resulting in an oversubscribed €700M fund.
Fergal Mullen, co-founder and partner at Highland Europe, said: “During 2020 we have seen 10-year trends in tech adoption compressed into one year across both consumer and business segments. Software has gone mainstream and it is mission-critical. The opportunity at the growth stage in Europe has never been more evident or more urgent. Highland Europe’s role is to bring capital, our deep network and scaling expertise to companies that can make it all the way to IPO. We have the track record, the team and a highly selective and focused strategy to help Europe’s most promising tech businesses become global leaders.”
‘Growth funding deficit’
Scaling software businesses to become global leaders requires expertise, insight and capital. Europe’s tech companies are proliferating at Seed and Series A, but remain starved of funding at growth stage. Figures from Dealroom.co show that European companies raised 38% of global venture capital at Seed, but this figure dropped to 21% at Series B and 14% at Series C (rounds of €40-100M). Until this is fixed, Europe will not reach its full potential, let alone challenge the dominance of the American and Asian tech giants.
Without good European sources of capital, many promising tech companies will struggle to raise the funds needed to fuel international success. According to one estimate, just one in eight European companies reach scale, compared with one in four in America. Highland Europe is determined to address this massive opportunity with a continued focus on mission-critical growth stage software and consumer technology companies, which have demonstrated compelling market traction and global ambition.
--ENDS--
About Highland Europe
Highland Europe invests in exceptional growth-stage software and internet companies. Active in Europe since 2003 as Highland Capital Partners and formally launched in 2012, Highland Europe has raised over €1.8 billion and has invested in companies such as Adjust, AMCS, Camunda, ContentSquare, Featurespace, GetYourGuide, Huel, Jellysmack, Malwarebytes, MatchesFashion, NewVoiceMedia, Nexthink, Spot, Supermetrics, WeTransfer, Wolt and Zwift. Highland’s collective history of investments across the US, Europe and China includes 46 IPOs and 19 billion-dollar-plus companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201206005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom